KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Gross Margin (2016 - 2025)

NovoCure (NVCR) has disclosed Gross Margin for 12 consecutive years, with 75.82% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 343.0% to 75.82% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 74.54% through Dec 2025, down 280.0% year-over-year, with the annual reading at 74.54% for FY2025, 280.0% down from the prior year.
  • Gross Margin hit 75.82% in Q4 2025 for NovoCure, up from 73.25% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 80.41% in Q1 2021 to a low of 73.01% in Q2 2023.
  • Historically, Gross Margin has averaged 76.75% across 5 years, with a median of 77.07% in 2024.
  • Biggest five-year swings in Gross Margin: soared 447bps in 2021 and later plummeted -675bps in 2023.
  • Year by year, Gross Margin stood at 77.71% in 2021, then dropped by 0bps to 77.51% in 2022, then fell by -2bps to 75.67% in 2023, then grew by 5bps to 79.25% in 2024, then decreased by -4bps to 75.82% in 2025.
  • Business Quant data shows Gross Margin for NVCR at 75.82% in Q4 2025, 73.25% in Q3 2025, and 73.88% in Q2 2025.